Quantcast

BioSpain 2014 Expands its Investment Forum Through Wider Range of Investor Profiles and more Participating Companies - abc27 WHTM

BioSpain 2014 Expands its Investment Forum Through Wider Range of Investor Profiles and more Participating Companies

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ASEBIO (Spanish Bioindustry Association)

MADRID, July 16, 2014 /PRNewswire/ --


Biospain 2014 is currently seeking and selecting projects for presentation as part of its Investment Forum, one of the most high profile in the sector, for which 25 investment funds - 70% of which are international- have already confirmed their attendance, a figure the organisers expect to double.

     (Logo: http://photos.prnewswire.com/prnh/20140716/697032 )

This year the Forum will be bolstered by the presence of a wider range of investor profiles, a bigger international presence and more participating companies.  

There are currently 10 available slots for companies and other entities wishing to pitch a business plan to the attending investors. In total, there will be 40 presentations over the three day duration of Biospain, each lasting 8-10 minutes, with alternating conferences on a wide range of investment issues (including corporate funds for big pharma, large international funds, PPP initiatives, business angels, industrial capital from non-pharma sectors and crowdfunding, to name a few).    

Among the most important funds to attend Biospain feature companies such as Aravis Ventures (Switzerland), Caixa Capital Risc (Spain), Cross Road Biotech (Spain), Edmond de Rothschild Investment  Partners (France), Forbion Capital Partners (Netherlands), Index Ventures (Switzerland), Johnson & Johnson Development Corporation (UK), LG Life Sciences (South Korea), Merck Serono Ventures (Germany), Novartis Venture Fund (Switzerland), Sofinnova Partners (France), Takeda Ventures (US), Ysios Capital Partners (Spain), Glaxo SmithKline Pharmaceuticals (UK) y Warburg Pincus (UK).

BioSpain 2014 (http://www.biospain2014.org), the 7th International Biotechnology Conference, is a biennial event which will take place from the 24th to the 26th of September in the Palacio de Congresos y Exposiciones de Galicia (Galicia Conference Centre), Santiago de Compostela (A Coruña). It is organised by the Spanish Bioindustry Association (ASEBIO) and on this edition, also by the Autonomous Government of Galicia, the University of santiago de Compostela, the University of Vigo and Santiago City Council.

Stand space at the trade fair is experiencing high demand, with 80% already allocated to exhibitors.  

So far we can confirm the attendance of over 100 companies and other entities from 20 countries, including delegations from countries such as Portugal, Canada, Colombia, Mexico, Russia, the UK and India. Biospain expects to attract 2000 participants - 10% more than in 2012 - exceeding the benchmark set that year of 800 companies and institutions from 40 countries.

BioSpain 2014 is sponsored by Bioibérica, Merck, MSD, Zeltia Group, Roche Institute and CLAMBER (Castilla La Mancha Bioeconomy Region).

Lucía Cecilia
Head of Communications for BioSpain 2014 and ASEBIO
landline. + 34-912109374/10
mobile: + 34-663 117-293    
e-mail: lcecilia@asebio.com / lcecilia@biospain2014.org


©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow